Cover Image
市場調查報告書

糖尿病腎病變 : 開發平台分析

Diabetic Nephropathy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192557
出版日期 內容資訊 英文 220 Pages
訂單完成後即時交付
價格
Back to Top
糖尿病腎病變 : 開發平台分析 Diabetic Nephropathy - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 220 Pages
簡介

所謂糖尿病腎病變是由糖尿病引發的腎臟損傷。主要的症狀有蛋白尿,及腎小球濾過率低,高血壓等。致病的危險因子有肥胖症和高血壓、高脂肪血·高糖血、抽煙等。可用藥物兩用和改善飲食等方式緩和症狀。

本報告提供全球各國的糖尿病腎病變治療用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

糖尿病腎病變概要

治療藥的開發

  • 糖尿病腎病變開發中產品:概要
  • 糖尿病腎病變開發中產品:比較分析

各企業正在開發的糖尿病腎病變治療藥

大學/研究機關研究中的糖尿病腎病變治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

糖尿病腎病變治療藥:開發中的產品一覽(各企業)

糖尿病腎病變治療藥:研究中的產品一覽(大學/研究機關別)

糖尿病腎病變開發治療藥的企業

  • AbbVie Inc.
  • Antisense Therapeutics Limited
  • Arena Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • BiOrion Technologies B.V.
  • Boehringer Ingelheim GmbH
  • Cellmid Limited
  • ChemoCentryx, Inc.
  • Concert Pharmaceuticals, Inc.
  • CSL Limited
  • 第一三共
  • Dimerix Bioscience Pty Ltd
  • Dong Wha Pharma Co., Ltd.
  • Dynamis Therapeutics, Inc.
  • Eli Lilly and Company
  • Galectin Therapeutics, Inc.
  • GenKyoTex S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • GNI Group Ltd.
  • Islet Sciences, Inc.
  • Jenrin Discovery, Inc.
  • Johnson & Johnson
  • Mallinckrodt Plc
  • Mesoblast Limited
  • 田邊三菱製藥
  • MorphoSys AG
  • NephroGenex, Inc.
  • Noxxon Pharma AG
  • Omeros Corporation
  • 大塚集團
  • Pfizer Inc.
  • PhytoHealth Corporation
  • ProMetic Life Sciences Inc.
  • Serodus ASA
  • Shire Plc
  • 武田藥品工業
  • Theravance Biopharma, Inc.
  • Tobira Therapeutics, Inc.
  • Vascular Pharmaceuticals, Inc.
  • Vicore Pharma AB
  • XOMA Corporation

糖尿病腎病變:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • 11-RVIVIT
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • 11-RVIVIT
  • A-717
  • Antibodies to Inhibit Heparanase for Cancer
  • APD-371
  • APX-115
  • ASP-8232
  • ATL-1103
  • atrasentan hydrochloride
  • baricitinib
  • BI-703704
  • Biologic for Diabetic Nephropathy
  • BOT-191
  • C-21
  • canagliflozin
  • CCX-140
  • cenicriviroc mesylate
  • corticotropin
  • CS-3150
  • CSL-346
  • CTP-499
  • Cyndacel-M
  • DMX-250
  • Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders
  • DT-23552
  • DW-1029M
  • DYN-12
  • emapticap pegol
  • finerenone
  • gevokizumab
  • GKT-136901
  • GKT-831
  • GRMD-02
  • GW-610742
  • JD-5037
  • JNJ-39933673
  • Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications
  • Monoclonal Antibody to Inhibit Midkine for Cancer, Metabolic Disorders and Kidney Diseases
  • MOR-107
  • MPC-300IV
  • MT-3995
  • Nephrilin
  • oxypurinol
  • PBI-4050
  • PBI-4547
  • PF-00489791
  • PHN-033
  • pirfenidone
  • probucol
  • Pyridoxamine Dihydrochloride
  • selonsertib
  • SER-150
  • SHP-627
  • Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy
  • Small Molecules for Diabetic Nephropathy
  • Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders
  • Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy
  • SP-20202
  • TAK-272
  • TAK-648
  • TBE-31
  • TD-0714
  • VPI-2690B
  • VS-105
  • XRX-108
  • XRX-221

糖尿病腎病變治療藥:開發中產品的最新趨勢

糖尿病腎病變治療藥:開發暫停的產品

糖尿病腎病變治療藥:開發中止的產品

糖尿病腎病變相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8347IDB

Summary

Global Markets Direct's, 'Diabetic Nephropathy - Pipeline Review, H2 2016', provides an overview of the Diabetic Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy
  • The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Nephropathy Overview
  • Therapeutics Development
    • Pipeline Products for Diabetic Nephropathy - Overview
    • Pipeline Products for Diabetic Nephropathy - Comparative Analysis
  • Diabetic Nephropathy - Therapeutics under Development by Companies
  • Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes
  • Diabetic Nephropathy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Diabetic Nephropathy - Products under Development by Companies
  • Diabetic Nephropathy - Products under Investigation by Universities/Institutes
  • Diabetic Nephropathy - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Ampio Pharmaceuticals, Inc.
    • Antisense Therapeutics Limited
    • Araim Pharmaceuticals, Inc.
    • Arena Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bayer AG
    • BiOrion Technologies B.V.
    • Boehringer Ingelheim GmbH
    • Cellmid Limited
    • ChemoCentryx, Inc.
    • CSL Limited
    • Daiichi Sankyo Company, Limited
    • Dimerix Bioscience Pty Ltd
    • Dong Wha Pharma Co., Ltd.
    • Dynamis Therapeutics, Inc.
    • Eli Lilly and Company
    • Galectin Therapeutics, Inc.
    • GenKyoTex S.A.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • Glucox Biotech AB
    • GNI Group Ltd.
    • Islet Sciences, Inc.
    • Jenrin Discovery, Inc.
    • Johnson & Johnson
    • Mallinckrodt Plc
    • Mesoblast Limited
    • Mitsubishi Tanabe Pharma Corporation
    • MorphoSys AG
    • Noxxon Pharma AG
    • Omeros Corporation
    • Otsuka Holdings Co., Ltd.
    • PhytoHealth Corporation
    • ProMetic Life Sciences Inc.
    • Serodus ASA
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma, Inc.
    • Tobira Therapeutics, Inc.
    • Vascular Pharmaceuticals, Inc.
    • Vicore Pharma AB
  • Diabetic Nephropathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 11-RVIVIT - Drug Profile
    • A-717 - Drug Profile
    • Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
    • APD-371 - Drug Profile
    • APX-115 - Drug Profile
    • ASP-8232 - Drug Profile
    • ATL-1103 - Drug Profile
    • atrasentan hydrochloride - Drug Profile
    • baricitinib - Drug Profile
    • BI-703704 - Drug Profile
    • BOT-191 - Drug Profile
    • C-21 - Drug Profile
    • canagliflozin - Drug Profile
    • CCX-140 - Drug Profile
    • cenicriviroc mesylate - Drug Profile
    • cibinetide - Drug Profile
    • corticotropin - Drug Profile
    • CS-3150 - Drug Profile
    • CSL-346 - Drug Profile
    • Cyndacel-M - Drug Profile
    • danazol - Drug Profile
    • DMX-250 - Drug Profile
    • DT-23552 - Drug Profile
    • DW-1029M - Drug Profile
    • DYN-12 - Drug Profile
    • emapticap pegol - Drug Profile
    • finerenone - Drug Profile
    • GKT-136901 - Drug Profile
    • GKT-831 - Drug Profile
    • GRMD-02 - Drug Profile
    • GW-610742 - Drug Profile
    • IP-9 - Drug Profile
    • JD-5037 - Drug Profile
    • JNJ-39933673 - Drug Profile
    • MG-132 - Drug Profile
    • Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile
    • MOR-107 - Drug Profile
    • MPC-300IV - Drug Profile
    • MT-3995 - Drug Profile
    • Nephrilin - Drug Profile
    • Orbcel-M - Drug Profile
    • oxypurinol - Drug Profile
    • PBI-4050 - Drug Profile
    • PBI-4547 - Drug Profile
    • PHN-033 - Drug Profile
    • pirfenidone - Drug Profile
    • probucol - Drug Profile
    • selonsertib - Drug Profile
    • SER-150 - Drug Profile
    • Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile
    • Small Molecules for Diabetic Nephropathy - Drug Profile
    • Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile
    • Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
    • SP-20202 - Drug Profile
    • TAK-272 - Drug Profile
    • TBE-31 - Drug Profile
    • TD-0714 - Drug Profile
    • VPI-2690B - Drug Profile
    • VS-105 - Drug Profile
    • XRX-108 - Drug Profile
    • XRX-221 - Drug Profile
  • Diabetic Nephropathy - Dormant Projects
  • Diabetic Nephropathy - Discontinued Products
  • Diabetic Nephropathy - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Nephropathy, H2 2016
  • Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Diabetic Nephropathy - Pipeline by AbbVie Inc, H2 2016
  • Diabetic Nephropathy - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by Antisense Therapeutics Limited, H2 2016
  • Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2016
  • Diabetic Nephropathy - Pipeline by Bayer AG, H2 2016
  • Diabetic Nephropathy - Pipeline by BiOrion Technologies B.V., H2 2016
  • Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Diabetic Nephropathy - Pipeline by Cellmid Limited, H2 2016
  • Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by CSL Limited, H2 2016
  • Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016
  • Diabetic Nephropathy - Pipeline by Dong Wha Pharma Co., Ltd., H2 2016
  • Diabetic Nephropathy - Pipeline by Dynamis Therapeutics, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H2 2016
  • Diabetic Nephropathy - Pipeline by Galectin Therapeutics, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H2 2016
  • Diabetic Nephropathy - Pipeline by Gilead Sciences, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H2 2016
  • Diabetic Nephropathy - Pipeline by GNI Group Ltd., H2 2016
  • Diabetic Nephropathy - Pipeline by Islet Sciences, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by Jenrin Discovery, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2016
  • Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H2 2016
  • Diabetic Nephropathy - Pipeline by Mesoblast Limited, H2 2016
  • Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Diabetic Nephropathy - Pipeline by MorphoSys AG, H2 2016
  • Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2016
  • Diabetic Nephropathy - Pipeline by Omeros Corporation, H2 2016
  • Diabetic Nephropathy - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H2 2016
  • Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by Serodus ASA, H2 2016
  • Diabetic Nephropathy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Diabetic Nephropathy - Pipeline by Theravance Biopharma, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by Tobira Therapeutics, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals, Inc., H2 2016
  • Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Diabetic Nephropathy - Dormant Projects, H2 2016
  • Diabetic Nephropathy - Dormant Projects (Contd..1), H2 2016
  • Diabetic Nephropathy - Dormant Projects (Contd..2), H2 2016
  • Diabetic Nephropathy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Diabetic Nephropathy, H2 2016
  • Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top